This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA
by Zacks Equity Research
bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
by Zacks Equity Research
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
by Zacks Equity Research
Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
by Zacks Equity Research
Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
by Kinjel Shah
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 27% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 27.1% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201
by Zacks Equity Research
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
by Zacks Equity Research
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics
by Zacks Equity Research
BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.
Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
by Zacks Equity Research
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
by Zacks Equity Research
Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.
Immunocore Holdings PLC Sponsored ADR (IMCR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now
by Zacks Equity Research
Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
by Zacks Equity Research
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation
by Zacks Equity Research
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
by Zacks Equity Research
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%
by Zacks Equity Research
The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals
by Zacks Equity Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.
Teva Pharmaceutical (TEVA) Names Richard Francis as New CEO
by Zacks Equity Research
Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.
Zacks.com featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares
by Zacks Equity Research
Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares are part of the Zacks Screen of the Week article.
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, EDAP, BBSI, OSBC and MNSB.